Stock Track | CooperCompanies Stock Plunges 7.95% Despite Solid Q1 Results and Raised FY2025 Guidance

Stock Track

Mar 07, 2025

CooperCompanies (NASDAQ: COO), a leading medical device company, saw its stock plunge 7.95% in after-hours trading on Thursday, March 6, despite reporting solid fiscal first-quarter 2025 results and raising its full-year guidance.

For the quarter ended January 31, 2025, CooperCompanies delivered a 4% year-over-year increase in revenue to $964.7 million, with its CooperVision segment growing 6% organically and CooperSurgical segment up 2% organically. Non-GAAP diluted earnings per share came in at $0.92, up from $0.85 in the prior-year period.

Encouraged by the strong start to the fiscal year, the company raised its full-year 2025 non-GAAP EPS guidance to a range of $3.94 to $4.02, up from its previous outlook of $3.92 to $4.02. Management commented on their confidence in delivering robust growth and operational excellence going forward.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1182362619"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1182362619\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1182362619?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-07 05:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182362619","market":"hk","top_or_hot":-1,"title":"Stock Track | CooperCompanies Stock Plunges 7.95% Despite Solid Q1 Results and Raised FY2025 Guidance","media":"Stock Track","content":"<p>CooperCompanies (NASDAQ: COO), a leading medical device company, saw its stock plunge 7.95% in after-hours trading on Thursday, March 6, despite reporting solid fiscal first-quarter 2025 results and raising its full-year guidance.</p>\n\n<p>For the quarter ended January 31, 2025, CooperCompanies delivered a 4% year-over-year increase in revenue to $964.7 million, with its CooperVision segment growing 6% organically and CooperSurgical segment up 2% organically. Non-GAAP diluted earnings per share came in at $0.92, up from $0.85 in the prior-year period.</p>\n\n<p>Encouraged by the strong start to the fiscal year, the company raised its full-year 2025 non-GAAP EPS guidance to a range of $3.94 to $4.02, up from its previous outlook of $3.92 to $4.02. Management commented on their confidence in delivering robust growth and operational excellence going forward.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CooperCompanies Stock Plunges 7.95% Despite Solid Q1 Results and Raised FY2025 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CooperCompanies Stock Plunges 7.95% Despite Solid Q1 Results and Raised FY2025 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-03-07 05:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CooperCompanies (NASDAQ: COO), a leading medical device company, saw its stock plunge 7.95% in after-hours trading on Thursday, March 6, despite reporting solid fiscal first-quarter 2025 results and raising its full-year guidance.</p>\n\n<p>For the quarter ended January 31, 2025, CooperCompanies delivered a 4% year-over-year increase in revenue to $964.7 million, with its CooperVision segment growing 6% organically and CooperSurgical segment up 2% organically. Non-GAAP diluted earnings per share came in at $0.92, up from $0.85 in the prior-year period.</p>\n\n<p>Encouraged by the strong start to the fiscal year, the company raised its full-year 2025 non-GAAP EPS guidance to a range of $3.94 to $4.02, up from its previous outlook of $3.92 to $4.02. Management commented on their confidence in delivering robust growth and operational excellence going forward.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"COO","symbol_name":"库珀医疗","start_time":0,"source_url":"","article_id":"1182362619","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182362619","pubTimestamp":1741296992,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"CooperCompanies , a leading medical device company, saw its stock plunge 7.95% in after-hours trading on Thursday, March 6, despite reporting solid fiscal first-quarter 2025 results and raising its full-year guidance.For the quarter ended January 31, 2025, CooperCompanies delivered a 4% year-over-year increase in revenue to $964.7 million, with its CooperVision segment growing 6% organically and CooperSurgical segment up 2% organically. Non-GAAP diluted earnings per share came in at $0.92, up fr","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"COO":"库珀医疗"},"translate_title":"尽管第一季度业绩稳健并上调了2025财年指引，但CooperCompanies股价仍暴跌7.95%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COO":1},"content_text":"CooperCompanies (NASDAQ: COO), a leading medical device company, saw its stock plunge 7.95% in after-hours trading on Thursday, March 6, despite reporting solid fiscal first-quarter 2025 results and raising its full-year guidance.\nFor the quarter ended January 31, 2025, CooperCompanies delivered a 4% year-over-year increase in revenue to $964.7 million, with its CooperVision segment growing 6% organically and CooperSurgical segment up 2% organically. Non-GAAP diluted earnings per share came in at $0.92, up from $0.85 in the prior-year period.\nEncouraged by the strong start to the fiscal year, the company raised its full-year 2025 non-GAAP EPS guidance to a range of $3.94 to $4.02, up from its previous outlook of $3.92 to $4.02. Management commented on their confidence in delivering robust growth and operational excellence going forward.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}